TheraRadar

Pharma Intelligence, Simplified

← Back
Data updated: Mar 10, 2026

TP ANDA HOLDINGS

CardiovascularDermatologyOncology
Generics

TP ANDA HOLDINGS is a generic drug manufacturer focused on Cardiovascular, Dermatology, Oncology. Key products include SERTRALINE HYDROCHLORIDE.

1985
Since
23
Drugs
-
Trials
161
Approved (2yr)

Key Drugs

No active drugs

Recent Activity

SERTRALINE HYDROCHLORIDE 2026-01-29
CLOMIPRAMINE HYDROCHLORIDE 2026-01-28
Labeling
SERTRALINE HYDROCHLORIDE 2026-01-28
BETAMETHASONE DIPROPIONATE 2026-01-26
SERTRALINE HYDROCHLORIDE 2026-01-20
SERTRALINE HYDROCHLORIDE 2026-01-20
SERTRALINE HYDROCHLORIDE 2026-01-20
SAPROPTERIN DIHYDROCHLORIDE 2026-01-08
LORAZEPAM 2026-01-05
Labeling
NITROGLYCERIN 2025-12-18
SEC Filings Pro
Loading...

Therapeutic Focus

Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5

Cardiovascular 40%
2 drugs
Dermatology 20%
1 drugs
Oncology 20%
1 drugs
Gastroenterology 20%
1 drugs

Pipeline Strength Pro

Loading...

Competitors Pro

Pfizer big-pharma
Oncology, Dermatology, Gastroenterology
Baxter specialty
Cardiovascular, Oncology, Dermatology
Bayer big-pharma
Oncology, Cardiovascular, Dermatology
BAUSCH specialty
Dermatology, Cardiovascular, Gastroenterology
CASPER PHARMA LLC big-pharma
Oncology, Cardiovascular, Gastroenterology, Dermatology